TheraSphere™

Y90 Glass Microspheres

TheraSphere™ Administration Kit
TheraSphere™ Dose Vial
TheraSphere™ Microspheres and Human Hair
TheraSphere™ Administration Kit
TheraSphere™ Dose Vial
TheraSphere™ Microspheres and Human Hair

TheraSphere glass microspheres take advantage of a tumor’s hypervascularity and prioritize microsphere flow to the tumor. Because TheraSphere has high activity per sphere, fewer microspheres are needed to achieve the desired dose. The minimally embolic nature of TheraSphere preserves the patient’s vasculature and allows for safe and effective delivery of radiation without the risk of stasis and reflux and spares healthy tissue.

Key Resources

Explore

Product Description

TheraSphere glass microspheres take advantage of a tumor’s hypervascularity and prioritize microsphere flow to the tumor. Because TheraSphere has high activity per sphere, fewer microspheres are needed to achieve the desired dose. The minimally embolic nature of TheraSphere preserves the patient’s vasculature and allows for safe and effective delivery of radiation without the risk of stasis and reflux and spares healthy tissue.

TheraSphere allows for personalization of treatment and greater flexibility by offering a multitude of standard and custom dose vial options to meet individual patient treatment goals. TheraSphere has demonstrated treatment success in a range of scenarios: curative or palliative, livers with single or multifocal tumors, portal vein thrombosis (PVT), and using segmental or lobar approaches1-6.

  1. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52(5):1741–9
  2. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79(1):163–71 
  3. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826–37 
  4. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60(1):192–201 
  5. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497–507
  6. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920–8

 

Product Specifications and Sizes

TheraSphere consists of Y90 glass microspheres used in radiation treatment for patients with unresectable HCC.

TheraSphere

  • Insoluble glass microspheres with a mean diameter of 20 to 30 μm
  • Y90 is an integral constituent of the glass

Y90

  • Pure beta emitter
  • Average energy of 0.9367 MeV
  • Physical half-life of 64.1 hours (2.67 days)

Ordering Information

The TheraSphere iDOC™ is an interactive Dose Ordering Calculator that will assist in calculating and ordering the appropriate TheraSphere dose vial size. The calculations are based upon the desired dose, timing of administration, lung shunt fraction, anticipated residual waste, and previous dose to the lungs.

Supported Browsers: Chrome (24+), Firefox (18+), Safari (5.1+), Opera (12+) and Internet Explorer (9+).

Your data will not be retained once you place an order or navigate away from TheraSphere iDOC page. If you know the dose you require, please proceed to our online order form or learn more about our y90 treatment and how they can help treat hepatocellular carcinoma (HCC).

 

Top